At MIOT International, cancer care goes beyond treatment it focuses on restoring hope, improving quality of life, and delivering outcomes even in the most complex cases.
This case highlights how a multidisciplinary, precision-based approach transformed a seemingly untreatable condition into a story of recovery.

Patient Case Image

A 74-year-old patient from the Republic of Congo presented with advanced-stage cancer under critical condition.

Initial Condition

  • Bedridden for several months with severe pain
  • Dependent on urinary catheter for over 6 months
  • Significant difficulty in bowel movement
  • Persistent abdominal and pelvic discomfort

Disease Progression

Further evaluation revealed:

  • Cancer widely spread to lungs, bones, and lymph nodes
  • Large prostate tumour extending to surrounding regions
  • Kidney failure requiring dialysis due to urinary obstruction
  • Elevated PSA levels indicating aggressive disease
Image 1
Image 2
Image 3

The overall prognosis appeared extremely poor, with very limited treatment options.

Clinical Challenge

The case posed multiple complexities:

  • Advanced metastatic disease
  • Compromised kidney function
  • Poor general condition and mobility
  • High risk for conventional therapies

At this stage, treatment required not just intervention but precision planning and coordinated expertise.

MIOT’s Multidisciplinary Approach

When conventional pathways offered little hope, MIOT adopted a collaborative, patient-specific strategy.

Tumour Board Intervention

A 35-member multidisciplinary team from the departments of Nuclear Medicine, Oncology, and Urology worked together to design a tailored treatment plan.

A carefully calibrated approach was initiated:

  • Advanced Radioligand Therapy for targeted cancer treatment
  • Dose optimisation to protect kidney function
  • Integration of supportive therapies for systemic stability
  • Continuous monitoring throughout treatment

This approach ensured both effectiveness and safety, even in a high-risk scenario.

Role of Advanced Imaging & Theranostics

MIOT’s strength in Nuclear Medicine and Theranostics played a critical role.

Key Advantages

  • Precision imaging using advanced modalities such as PSMA PET-CT
  • Accurate identification of disease spread
  • Ability to target cancer cells at a molecular level
  • Real-time monitoring of treatment response

This allowed for highly personalised and adaptive treatment planning.

Clinical Outcome

The results demonstrated a remarkable turnaround.

Image 1
Image 2
Image 3

Recovery Milestones

  • Significant recovery within 3 months
  • Transition from bedridden to walking
  • Marked reduction in pain
  • Improved bowel function

Biological Response

  • Tumour markers reduced by more than 50%
  • Completion of 3 treatment cycles
  • Overall clinical condition stabilised

Radiological Improvement

  • Resolution of lung metastases
  • No active lymph node involvement
  • Significant reduction in bone lesions

Impact on Patient Quality of Life

Beyond clinical metrics, the most important outcome was:

  • Restoration of independence
  • Improved physical strength and energy
  • Enhanced overall well-being

This reflects MIOT’s core philosophy—treating the patient, not just the disease.

MIOT International continues to lead in advanced cancer care through:

  • Expertise in Theranostics and Nuclear Medicine
  • Capability to manage complex and rare cases
  • Strong multidisciplinary collaboration
  • Focus on both survival and quality of life
  • Access to cutting-edge technology and protocols

This case exemplifies how innovation, collaboration, and precision medicine can redefine outcomes—even in the most challenging scenarios.

At MIOT, advanced cancer care is not just about extending life—it is about restoring dignity, function, and hope.

To know more about the department of MIOT Institute of Cancer Cure visit : MIOT Institute of Cancer Cure

To know more about the department of Nuclear Medicine visit : Nuclear Medicine & PET CT